{"id":689931,"date":"2022-09-28T16:32:28","date_gmt":"2022-09-28T20:32:28","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/lyell-immunopharma-announces-the-appointment-of-rahsaan-thompson-as-chief-legal-officer\/"},"modified":"2022-09-28T16:32:28","modified_gmt":"2022-09-28T20:32:28","slug":"lyell-immunopharma-announces-the-appointment-of-rahsaan-thompson-as-chief-legal-officer","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/lyell-immunopharma-announces-the-appointment-of-rahsaan-thompson-as-chief-legal-officer\/","title":{"rendered":"Lyell Immunopharma Announces the Appointment of Rahsaan Thompson as Chief Legal Officer"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"justify\">SOUTH SAN FRANCISCO, Calif., Sept.  28, 2022  (GLOBE NEWSWIRE) &#8212; Lyell Immunopharma, Inc. (Nasdaq: LYEL), a clinical\u2011stage T-cell reprogramming company dedicated to developing curative cell therapies for patients with solid tumors, announced that Rahsaan W. Thompson has joined the executive management team as chief legal officer. A biopharmaceutical industry veteran, Mr. Thompson has more than 20 years of experience with development stage and commercial companies.<\/p>\n<p align=\"justify\">\u201cRahsaan\u2019s experience and expertise across corporate law and intellectual property make him an ideal fit for Lyell as we advance clinical development of multiple products in our pipeline targeting solid tumor cancers,\u201d said\u00a0Liz Homans, chief executive officer of Lyell. \u201cWe are delighted to welcome him to the team.\u201d<\/p>\n<p align=\"justify\">\u201cLyell\u2019s commitment to advancing innovative science is truly inspiring. I am excited to join the team and contribute to the ambitious mission of developing curative cell therapies for patients with limited treatment options,\u201d said Mr. Thompson.<\/p>\n<p align=\"justify\">Before joining Lyell, Mr.\u00a0Thompson was executive vice president and general counsel at Gritstone bio, where he was responsible for all legal aspects of corporate strategy, intellectual property, transactions, compliance and litigation matters. Mr.\u00a0Thompson was also general counsel for Opiant Pharmaceuticals. Previously, as the vice president of law for Actelion Pharmaceuticals, he led the Actelion law department in San Francisco. Before joining Actelion, he worked for the law firm of Quarles\u00a0&amp;\u00a0Brady in Chicago. Mr.\u00a0Thompson was the associate general counsel at Abraxis Bioscience before its acquisition by Celgene. Mr.\u00a0Thompson also served as corporate counsel at McKesson Corporation. He began his career as an assistant district attorney in the Philadelphia District Attorney\u2019s office. Mr. Thompson obtained his bachelor\u2019s degree from Southern Methodist University and his law degree from Hofstra University. He has served on various non-profit boards and presently serves as Chair of the Board of Directors for the Oakland Museum of California.<\/p>\n<p align=\"justify\">\n        <strong>About Lyell Immunopharma, Inc.<\/strong>\n      <\/p>\n<p align=\"justify\">Lyell is a clinical-stage T-cell reprogramming company dedicated to developing curative cell therapies for patients with solid tumors. The Company is advancing a pipeline of therapies designed to address what it believes are the primary barriers that limit consistent, reliable and curative responses to adoptive T-cell therapy: T-cell exhaustion and lack of durable stemness, which includes the ability to proliferate, persist and self-renew, as well as generate differentiated effector cell progenies to provide durable anti-tumor functionality. Lyell is applying its proprietary <em>ex vivo<\/em> genetic and epigenetic reprogramming technology platforms, Gen-R\u2122 and Epi-R\u2122, to address these barriers in order to develop new medicines with improved, durable and potentially curative clinical outcomes. Lyell is based in South San Francisco, California and Seattle and Bothell, Washington. To learn more, please visit <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=_lO82pvrTofgkd9Fv3WfJjrQViJ7gmAJRYTqn_YN8QXo6U0B4ZIyLCY7hO8mjzedZyceL2KlEAY9Bj2FaarKTw==\" rel=\"nofollow noopener\" target=\"_blank\">www.lyell.com<\/a>.<\/p>\n<p align=\"justify\">\n        <strong>Forward Looking Statements <\/strong>\n      <\/p>\n<p align=\"justify\">This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements expressed or implied in this press release include, but are not limited to, statements regarding: Lyell\u2019s plan to advance clinical development of multiple products targeting solid tumor cancers; Lyell\u2019s mission of developing curative cell therapies for patients with limited treatment options; the therapeutic potential of Lyell\u2019s product candidates targeting solid tumor cancers; the anticipated benefits of Mr.\u00a0Thompson\u2019s joining the executive management team; and other statements that are not historical fact. These statements are based on Lyell\u2019s current plans, objectives, estimates, expectations and intentions, are not guarantees of future performance and inherently involve significant risks and uncertainties. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties, which include, but are not limited to, risks and uncertainties related to: the effects of the evolving COVID-19 pandemic; geopolitical instability; Lyell\u2019s ability to submit planned INDs or initiate and execute clinical trials on the anticipated timelines, if at all; Lyell\u2019s ability to manufacture and supply its product candidates for its clinical trials; the preclinical profiles of Lyell\u2019s product candidates not translating in clinical trials; the potential for results from clinical trials to differ from preclinical, early clinical, preliminary or expected results; significant adverse events, toxicities or other undesirable side effects associated with Lyell\u2019s product candidates; the significant uncertainty associated with Lyell\u2019s product candidates ever receiving any regulatory approvals; Lyell\u2019s ability to obtain, maintain or protect intellectual property rights related to its product candidates; implementation of Lyell\u2019s strategic plans for its business and product candidates; Lyell\u2019s reliance on GSK to advance the development of its NY-ESO-1 programs; the sufficiency of Lyell\u2019s capital resources and need for additional capital to achieve its goals; and other risks, including those described under the heading \u201cRisk Factors\u201d in Lyell\u2019s most recently filed periodic reports on Form\u00a010-K and Form\u00a010-Q and in Lyell\u2019s future reports to be filed with the U.S. Securities and Exchange Commission. Forward-looking statements contained in this press release are made as of this date, and Lyell undertakes no duty to update such information except as required under applicable law.<\/p>\n<p align=\"justify\">\n        <strong>Contact:<\/strong><br \/>\n        <br \/>Ellen Rose<br \/>Senior Vice President, Communications and Investor Relations<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=wOiYg0189UONY5c_wTWwHJeI5EIrHixq11eyQzRcDoN19zif2VSndGSN-wsYtSkvFfmAq5DJ2PL0HlQjWbWy0A==\" rel=\"nofollow noopener\" target=\"_blank\"><u>erose@lyell.com<\/u><\/a><\/p>\n<p \/>\n      <img decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODY1NDQ2NyM1MTc0OTkwIzIxODc2NTg=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" src=\"https:\/\/ml.globenewswire.com\/media\/ZGY3OGU4ZGEtMDRiNS00ZTY4LThmMTMtNTAyZDVkNGE4ZGQ5LTExOTkyMTE=\/tiny\/Lyell-Immunopharma-Inc.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>SOUTH SAN FRANCISCO, Calif., Sept. 28, 2022 (GLOBE NEWSWIRE) &#8212; Lyell Immunopharma, Inc. (Nasdaq: LYEL), a clinical\u2011stage T-cell reprogramming company dedicated to developing curative cell therapies for patients with solid tumors, announced that Rahsaan W. Thompson has joined the executive management team as chief legal officer. A biopharmaceutical industry veteran, Mr. Thompson has more than 20 years of experience with development stage and commercial companies. \u201cRahsaan\u2019s experience and expertise across corporate law and intellectual property make him an ideal fit for Lyell as we advance clinical development of multiple products in our pipeline targeting solid tumor cancers,\u201d said\u00a0Liz Homans, chief executive officer of Lyell. \u201cWe are delighted to welcome him to the team.\u201d \u201cLyell\u2019s commitment to advancing innovative science is &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/lyell-immunopharma-announces-the-appointment-of-rahsaan-thompson-as-chief-legal-officer\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Lyell Immunopharma Announces the Appointment of Rahsaan Thompson as Chief Legal Officer&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-689931","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Lyell Immunopharma Announces the Appointment of Rahsaan Thompson as Chief Legal Officer - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/lyell-immunopharma-announces-the-appointment-of-rahsaan-thompson-as-chief-legal-officer\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Lyell Immunopharma Announces the Appointment of Rahsaan Thompson as Chief Legal Officer - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"SOUTH SAN FRANCISCO, Calif., Sept. 28, 2022 (GLOBE NEWSWIRE) &#8212; Lyell Immunopharma, Inc. (Nasdaq: LYEL), a clinical\u2011stage T-cell reprogramming company dedicated to developing curative cell therapies for patients with solid tumors, announced that Rahsaan W. Thompson has joined the executive management team as chief legal officer. A biopharmaceutical industry veteran, Mr. Thompson has more than 20 years of experience with development stage and commercial companies. \u201cRahsaan\u2019s experience and expertise across corporate law and intellectual property make him an ideal fit for Lyell as we advance clinical development of multiple products in our pipeline targeting solid tumor cancers,\u201d said\u00a0Liz Homans, chief executive officer of Lyell. \u201cWe are delighted to welcome him to the team.\u201d \u201cLyell\u2019s commitment to advancing innovative science is &hellip; Continue reading &quot;Lyell Immunopharma Announces the Appointment of Rahsaan Thompson as Chief Legal Officer&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/lyell-immunopharma-announces-the-appointment-of-rahsaan-thompson-as-chief-legal-officer\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2022-09-28T20:32:28+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODY1NDQ2NyM1MTc0OTkwIzIxODc2NTg=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/lyell-immunopharma-announces-the-appointment-of-rahsaan-thompson-as-chief-legal-officer\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/lyell-immunopharma-announces-the-appointment-of-rahsaan-thompson-as-chief-legal-officer\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Lyell Immunopharma Announces the Appointment of Rahsaan Thompson as Chief Legal Officer\",\"datePublished\":\"2022-09-28T20:32:28+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/lyell-immunopharma-announces-the-appointment-of-rahsaan-thompson-as-chief-legal-officer\\\/\"},\"wordCount\":857,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/lyell-immunopharma-announces-the-appointment-of-rahsaan-thompson-as-chief-legal-officer\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODY1NDQ2NyM1MTc0OTkwIzIxODc2NTg=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/lyell-immunopharma-announces-the-appointment-of-rahsaan-thompson-as-chief-legal-officer\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/lyell-immunopharma-announces-the-appointment-of-rahsaan-thompson-as-chief-legal-officer\\\/\",\"name\":\"Lyell Immunopharma Announces the Appointment of Rahsaan Thompson as Chief Legal Officer - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/lyell-immunopharma-announces-the-appointment-of-rahsaan-thompson-as-chief-legal-officer\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/lyell-immunopharma-announces-the-appointment-of-rahsaan-thompson-as-chief-legal-officer\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODY1NDQ2NyM1MTc0OTkwIzIxODc2NTg=\",\"datePublished\":\"2022-09-28T20:32:28+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/lyell-immunopharma-announces-the-appointment-of-rahsaan-thompson-as-chief-legal-officer\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/lyell-immunopharma-announces-the-appointment-of-rahsaan-thompson-as-chief-legal-officer\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/lyell-immunopharma-announces-the-appointment-of-rahsaan-thompson-as-chief-legal-officer\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODY1NDQ2NyM1MTc0OTkwIzIxODc2NTg=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODY1NDQ2NyM1MTc0OTkwIzIxODc2NTg=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/lyell-immunopharma-announces-the-appointment-of-rahsaan-thompson-as-chief-legal-officer\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Lyell Immunopharma Announces the Appointment of Rahsaan Thompson as Chief Legal Officer\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Lyell Immunopharma Announces the Appointment of Rahsaan Thompson as Chief Legal Officer - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/lyell-immunopharma-announces-the-appointment-of-rahsaan-thompson-as-chief-legal-officer\/","og_locale":"en_US","og_type":"article","og_title":"Lyell Immunopharma Announces the Appointment of Rahsaan Thompson as Chief Legal Officer - Market Newsdesk","og_description":"SOUTH SAN FRANCISCO, Calif., Sept. 28, 2022 (GLOBE NEWSWIRE) &#8212; Lyell Immunopharma, Inc. (Nasdaq: LYEL), a clinical\u2011stage T-cell reprogramming company dedicated to developing curative cell therapies for patients with solid tumors, announced that Rahsaan W. Thompson has joined the executive management team as chief legal officer. A biopharmaceutical industry veteran, Mr. Thompson has more than 20 years of experience with development stage and commercial companies. \u201cRahsaan\u2019s experience and expertise across corporate law and intellectual property make him an ideal fit for Lyell as we advance clinical development of multiple products in our pipeline targeting solid tumor cancers,\u201d said\u00a0Liz Homans, chief executive officer of Lyell. \u201cWe are delighted to welcome him to the team.\u201d \u201cLyell\u2019s commitment to advancing innovative science is &hellip; Continue reading \"Lyell Immunopharma Announces the Appointment of Rahsaan Thompson as Chief Legal Officer\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/lyell-immunopharma-announces-the-appointment-of-rahsaan-thompson-as-chief-legal-officer\/","og_site_name":"Market Newsdesk","article_published_time":"2022-09-28T20:32:28+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODY1NDQ2NyM1MTc0OTkwIzIxODc2NTg=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/lyell-immunopharma-announces-the-appointment-of-rahsaan-thompson-as-chief-legal-officer\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/lyell-immunopharma-announces-the-appointment-of-rahsaan-thompson-as-chief-legal-officer\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Lyell Immunopharma Announces the Appointment of Rahsaan Thompson as Chief Legal Officer","datePublished":"2022-09-28T20:32:28+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/lyell-immunopharma-announces-the-appointment-of-rahsaan-thompson-as-chief-legal-officer\/"},"wordCount":857,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/lyell-immunopharma-announces-the-appointment-of-rahsaan-thompson-as-chief-legal-officer\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODY1NDQ2NyM1MTc0OTkwIzIxODc2NTg=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/lyell-immunopharma-announces-the-appointment-of-rahsaan-thompson-as-chief-legal-officer\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/lyell-immunopharma-announces-the-appointment-of-rahsaan-thompson-as-chief-legal-officer\/","name":"Lyell Immunopharma Announces the Appointment of Rahsaan Thompson as Chief Legal Officer - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/lyell-immunopharma-announces-the-appointment-of-rahsaan-thompson-as-chief-legal-officer\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/lyell-immunopharma-announces-the-appointment-of-rahsaan-thompson-as-chief-legal-officer\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODY1NDQ2NyM1MTc0OTkwIzIxODc2NTg=","datePublished":"2022-09-28T20:32:28+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/lyell-immunopharma-announces-the-appointment-of-rahsaan-thompson-as-chief-legal-officer\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/lyell-immunopharma-announces-the-appointment-of-rahsaan-thompson-as-chief-legal-officer\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/lyell-immunopharma-announces-the-appointment-of-rahsaan-thompson-as-chief-legal-officer\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODY1NDQ2NyM1MTc0OTkwIzIxODc2NTg=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODY1NDQ2NyM1MTc0OTkwIzIxODc2NTg="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/lyell-immunopharma-announces-the-appointment-of-rahsaan-thompson-as-chief-legal-officer\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Lyell Immunopharma Announces the Appointment of Rahsaan Thompson as Chief Legal Officer"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/689931","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=689931"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/689931\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=689931"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=689931"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=689931"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}